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Summary Objective: To determine whether initiation of maintenance treatment
with the salmeterol (S)/fluticasone propionate (FP) combination (Seretidet/Vianit/
Advairt) is more effective than inhaled steroid alone in patients with asthma
symptomatic on short-acting bronchodilator alone.
Design: 150 asthma patients with symptoms and prn use of short-acting
bronchodilator at least once a week were randomised to 24 weeks’ treatment with
either S/FP 50/100 mg bd (n ¼ 78) or FP 100 mg bd (n ¼ 72).
The primary endpoint was the percentage of symptom-free ‘dayþ night’s.
Results: The percentage of symptom-free ‘dayþ night’s increased significantly
more for S/FP (20 to 64%) compared to FP (24 to 51%). The treatment difference was
15.3%, P ¼ 0:008: In the sub-group of patients with mild asthma the treatment
difference was also statistically significant in favour of S/FP (P ¼ 0:0245; n ¼ 74).
S/FP was also significantly superior to FP alone for: lung function, salbutamol use
prn, day symptom score, symptom-free days, and episode-free ‘dayþ night’s.
Treatments were equally well tolerated.
Conclusion: Initial maintenance treatment with S/FP is significantly more
effective than with inhaled steroid alone for patients symptomatic when treated
with short-acting bronchodilator alone. This also apply to patients with mild
persistent asthma.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
The goal of asthma management is to achieve
and maintain disease control. With effective
treatment that targets the underlying com-
ponents of asthma, patients should be able to lead
a normal active life with a minimum of asthma
symptoms.
Inhaled corticosteroids (ICS) and long-acting b2-
agonists (LABA) have complementary modes of
action to treat the underlying components of
asthma. Therefore, it is reasonable to expect that
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combination treatment can offer greater asthma
control than monotherapy.
The Global INitiative for Asthma treatment
(GINA) Guidelines recommend a step-wise approach
to asthma treatment.1 According to GINA Guide-
lines, an asthmatic patient has persistent asthma if
a short-acting bronchodilator is used 1 or more
times a week.1 The stepwise approach to treatment
of asthma prescribes the initiation of maintenance
treatment with ICS together with a short-acting
bronchodilator as needed (mild asthma). If low
dose ICS fails to control asthma symptoms addition
of a long-acting inhaled bronchodilator is recom-
mended (moderate–severe asthma).1
Many studies have shown that the addition of a
LABA improves asthma control more than doubling
the dose of ICS for symptomatic patients with
moderate and severe asthma inadequately con-
trolled on their current ICS dose.2–6 This has also
been confirmed in a meta-analysis.7
The positive results are reflected in the GINA
Guidelines that recommend adding a LABA as a
preferred option to increasing the ICS dose in
patients who remain symptomatic on low-medium
dose ICS.1
By initiation of maintenance treatment asthma
patients may also benefit from adding a LABA to the
ICS. However, only few studies have evaluated
initial maintenance treatment options, specifically
ICS with a LABA in patients with asthma who had
not previously been treated with ICS.
Results from a pilot study by Pearlman et al.8
indicate that patients who are symptomatic on ‘as-
needed’ bronchodilators alone can derive greater
benefits from the concurrent use of salmeterol and
low dose ICS than inhaled ICS alone upon initiation
of maintenance asthma therapy. This was, however,
a study without a pre-defined primary efficacy
parameter.
This is the first study with the objective to
determine whether initiation of maintenance
treatment with the salmeterol/fluticasone propio-
nate (S/FP) combination (Seretidet) is more
effective in improving daily asthma control than
initiation of monotherapy with FP (Flixotidet)
alone in patients with persistent asthma sympto-
matic when treated with only a short-acting
bronchodilator, also for mild persistent asthma.
Methods
Study design
This study was conducted as a randomised, con-
trolled, double-blind, parallel-group, comparative
multi-centre study conducted in 45 centres in
Denmark (44 general practices and 1 hospital
department). After a 2-week baseline period
patients were randomised to treatment for 24
weeks with either S/FP 50/100 mg bd or FP
100 mg bd, both delivered via the Diskust. Patients
had 4 study visits at the clinic: visit 1 (screening),
visit 2 (randomisation), visit 3 (after 12 weeks
treatment), and visit 4 (after 24 weeks treatment).
Patients were allowed to use salbutamol prn for
symptom relief during the entire study period.
Study population
Male and female patients were eligible for the
study if they were at least 18 years of age, had an
asthma diagnosis as defined by the American
Thoracic Society,9 and used a short-acting bronch-
odilator once or more per week for relief of asthma
symptoms within 2 months prior to enrolment and
during the baseline period. According to the GINA
Guidelines they had persistent asthma.1
The asthma diagnosis had to be confirmed in the
clinical record forX3 months. The baseline diurnal
peak expiratory flow (PEF) variation had to be
X20% or one of the following determined within 3
years prior to baseline: (a) FEV1 reversibility X15%
in response to bronchodilator (b) PC20 metacholine
p4mg/ml (c) diurnal PEF variation X20%. Female
patients were required to have a negative preg-
nancy test. Patients were excluded if they experi-
enced an asthma exacerbation during the 2-week
baseline period.
Use of long-acting bronchodilators, ICS, or other
long-acting asthma medication were not allowed
within 2 months prior to visit 1. Use of oral/
parenteral corticosteroid therapy was not allowed
within 1 month prior to visit 1 but allowed between
visit 2 and 4.
Use of asthma medication other than study drug
and salbutamol was not allowed in the baseline and
treatment period of the study.
No other medication that might affect the course
of asthma or interfere with the study results was
permitted.
Patients were excluded from the study if they
had an upper or lower respiratory tract or middle
ear infection within 1 month prior to visit 1, serious
cardiovascular disease, diabetes mellitus, un-
treated hypokalaemia, or thyrotoxicosis. In addi-
tion, they were excluded if they had a known or
suspected hypersensitivity reaction to drug consti-
tuents, any other diseases that might interfere with
the study results, or had problems operating the
inhaler or peakflow meter.
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Smoking history was categorised as smoker, ex-
smoker (stopped smoking before visit 1), or never
smoked.
Measurements and evaluations
The primary efficacy parameter was the percen-
tage of symptom-free ‘dayþ night’s (24-h periods).
The following secondary efficacy parameters
were evaluated: lung function (morning and eve-
ning PEF), symptoms (day symptom score, night
symptom score, days and nights without symp-
toms), salbutamol use (number of episodes, ‘day-
þ night’s without salbutamol), episode-free
‘dayþ night’s (day symptom score¼ 0, night symp-
tom score¼ 0, no salbutamol use, no exacerba-
tions, no adverse events), exacerbations, and
adverse events.
During the baseline and treatment periods
patients completed diary cards each morning and
evening recording the following information: morn-
ing and evening PEF, day and night symptom scores,
and use of salbutamol prn for relief of symptoms.
PEF was measured using a Mini-Wrights peakflow
meter (Clement Clark) before study drug was
taken. The highest value of 3 readings was
recorded.
Day symptom score scale 0–5 (0¼No symptoms
during daytime, 1¼ Symptoms for a short period
during daytime, 2¼ Symptoms for two or more
short periods during daytime, 3¼ Symptoms for
most of the day, which did not affect your normal
daily activities, 4¼ Symptoms for most of the day,
which affected your normal daily activities,
5¼ Symptoms so severe, that you were unable to
work or perform your normal daily activities).
Night symptom score scale 0–4 (0¼No symptoms
during the night, 1¼ Symptoms causing you to wake
up once or wake early, 2¼ Symptoms causing you to
wake up twice or more (include waking up early),
3¼ Symptoms causing you to be awake for most of
the night, 4¼ Symptoms so severe, that you were
unable to sleep at all).
The investigator recorded adverse events at each
clinic visit and rated the severity of the event and
the perceived relationship of the event to the study
drug. The investigator also recorded all concurrent
medication and asthma exacerbations in the CRF at
the clinic visits. A moderate asthma exacerbation
was defined as a deterioration in asthma requiring
administration of ICS over and above current study
medication and/or oral corticosteroid and/or par-
enteral corticosteroid. A severe asthma exacerba-
tion was defined as a deterioration in asthma
requiring emergency hospital treatment. Orophar-
yngeal examination was performed at each visit.
Approval for the study was obtained from the
Danish Medicines Agency and scientific ethics
committees. All patients gave written informed
consent before any study procedures were carried
out.
The study was conducted in accordance with the
principles of Good Clinical Practice.
Statistical analysis
All efficacy parameters were analysed on an intent-
to-treat basis and data from all patients with at
least one dose of study drug were included in the
analysis.
A sample size of 72 in each treatment group
would have 90% power to detect a 20% difference in
means in the percentage of symptom-free ‘day-
þ night’s between treatment groups (assuming a
common standard deviation of 37%).
Comparisons of the treatments were performed
using analysis of variance (ANOVA). Due to baseline
dependence (Po0:0001) data were analysed with
baseline values as covariates.
All 95%-confidence intervals and all hypothesis
tests were 2-sided and conducted using a 5%
significance level.
The assessment period for efficacy analyses was
defined as two weeks after start of treatment until
end of treatment.
A sub-group analysis of patients with mild
persistent asthma was performed for patients with
a mean baseline morning PEFX80% of the predicted
PEF.1 Predicted normal values for lung function
were from Quanjer et al.10
Results
Study population
A total of 221 patients were screened and 150
patients were randomised to study treatment. 71
patients were not randomised because they with-
drew the consent (5), did not return to the clinic
(8), did not complete the diary (2), were protocol
violators or withdrawn by mistake (4), used
salbutamol for relief of symptoms less than once
per week (6), the diurnal PEF variation was o20%
and they did not have a historical lung function test
made within the last 3 years pre-study (38). 8
patients had other reasons for not being rando-
mised.
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Randomisation resulted in comparable treatment
groups at baseline with respect to patient demo-
graphics and pulmonary function (Table 1). The
majority of the patients were randomised based on
reversibility. Only 5 patients (3 in the S/FP group
and 2 in the FP group) were randomised based on
bronchial hyperreactivity.
132 patients completed the study, 67 (86%) in the
S/FP group and 59 (82%) in the FP group. Reasons
for withdrawals were comparable for the treat-
ment groups (Table 2).
Symptoms
The primary efficacy parameter was the percen-
tage of symptom-free ‘dayþ night’s (24-h periods).
Before initiation of maintenance treatment the
patients experienced symptoms on most days.
During the baseline period patients were only
symptom-free on 25 and 20% ‘dayþ night’s for the
FP and S/FP group, respectively. Study treatments
markedly increased the percentage of symptom-
free ‘dayþ night’s.
Patients receiving S/FP as initial maintenance
treatment achieved a significantly higher percen-
tage of symptom-free ‘dayþ night’s compared to
those receiving FP alone (Fig. 1). S/FP gave an
increase from 20% to 64% and FP from 24% to 51%.
The treatment difference was 13.2% in favour of S/
FP (P ¼ 0:035). When adjusted for baseline, the
treatment difference in favour of S/FP was 15.3%
(P ¼ 0:008).
The sub-analysis of symptom-free ‘dayþ night’s
in patients classified with mild asthma (58% of the
patients) also showed a statistically significant
difference in favour of S/FP compared with FP
alone (Fig. 1). The treatment difference was 16.9%,
P ¼ 0:025 (n ¼ 30 in S/FP group, n ¼ 44 in FP
group).
Use of salbutamol prn for relief of symptoms
S/FP was superior to FP alone in increasing the
percentage of ‘dayþ night’s (24-h periods) without
salbutamol use prn, Po0:05 (Table 3).
Lung function
Combination treatment with S/FP improved
morning PEF (P ¼ 0:0011) and evening PEF
(P ¼ 0:011) significantly more than monotherapy
with FP (Table 3).
Episode-free ‘dayþnight’s
The percentage of episode-free ‘dayþ night’s
increased from 15% to 60% with S/FP com-
pared with 17–47% with FP alone. The treatment
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Table 1 Patient baseline characteristics.
Characteristics,
mean7SD
S/FP
(n ¼ 78)
FP
(n ¼ 72)
Age (years) 39715 38715
Men/women (%) 49/51 38/63
Weight (kg) 79718 76714
Height (cm) 174711 17178
Asthma history (years) 13713 11710
Baseline morning PEF
(l/min)
3807117 3977109
% of predicted PEF 77721 83718
Smoking status (%)
Smoker/ex-smoker/
never smoked
32/26/42 46/24/31
Table 2
S/FP FP
Randomised, n (100%) 78 72
Completed, n (%) 67 (86%) 59 (82%)
Reasons for withdrawals n (%)
Adverse event 1 (1%) 2 (3%)
Informed consent withdrawn 1 (1%) 2 (3%)
Lost to follow-up 5 (6%) 6 (8%)
Protocol violation 3 (4%) 2 (3%)
Other 1 (1%) 1 (1%)
Figure 1 Symptom-free ‘dayþ night’s (24-h periods)
before and after initiation of maintenance treatment
with either S/FP 50/100 mg bd or FP 100 mg bd.
Initiation of maintenance treatment of persistent asthma 1011
difference of 14% was statistically significant in
favour of S/FP (P ¼ 0:015) (Fig. 2).
Asthma exacerbations
No difference in asthma exacerbations was ob-
served between treatment groups. No patients
experienced moderate exacerbations. Only 1 pa-
tient in each treatment group experienced a severe
exacerbation.
Safety
The combined use of salmeterol with FP was not
associated with additional safety risks compared
with monotherapy with FP, as measured by fre-
quency of adverse events.
The safety profiles observed in the study
were similar across treatment groups. 62% of
patients in the S/FP group and 58% of patients
in the FP group had at least one adverse event
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Figure 2 Episode-free ‘dayþ night’s (24-h periods)
before and after initiation of maintenance treatment
with either S/FP 50/100 mg bd or FP 100 mg bd. (Episode-
free ‘dayþ night’s: Day symptom score¼ 0, Night symp-
tom score¼ 0, no salbutamol use prn, no adverse events,
no exacerbations.)
Table 3 Effect of maintenance treatment.
Efficacy parameter Treatment Baseline Maintenance
treatment
Treatment
difference
p-value
Day symptom score S/FP 1.4 0.5 0.3 0.0047n
FP 1.3 0.7
Night symptom score S/FP 0.6 0.2 0.1 0.27
FP 0.5 0.2
Symptom-free days (%) S/FP 25 66 12.7 0.022n
FP 31 57
Symptom-free nights (%) S/FP 56 83 5.4 0.18
FP 61 80
‘Dayþ night’s without
salbutamol use prn (%)
S/FP 22 71 10.5 0.0497n
FP 25 63
Salbutamol use prn
(number of episodes
‘dayþ night’)
S/FP 2.3 1.1 0.3 0.14
FP 2.1 1.3
Morning PEF (l/min) S/FP 380 436 29.5 0.0011n
FP 397 420
Evening PEF (l/min) S/FP 408 448 21.1 0.011n
FP 418 432
Effect of initiation of maintenance treatment with S/EP 50/100 mg bd or FP 100mg bd. 24 weeks treatment. Mean values in the
baseline period (salbutamol prn only) and study treatment period.
nTreatment difference statistically significant in favour of S/FP.
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during the 24-weeks treatment. The most common
adverse events were headaches (28%), common
colds (8%), cough (7%), and back pain (5%).
1 patient in each treatment group had oral
candidiasis. 1 patient in the S/FP group and 2
patients in the FP group had a serious adverse
event. None of these serious adverse events
was considered related to the study drug.
Withdrawal from the study because of an adverse
event occurred in 3 patients (1 treated with S/FP
and 2 treated with FP).
Discussion
This was the first study designed primarily to
determine whether initiation of maintenance
treatment with the ICSþ LABA combination S/FP
lead to better asthma control with more day and
night’s without symptoms of the disease than
initiation of monotherapy with the ICS FP alone in
patients with persistent asthma symptomatic on
short-acting bronchodilator alone, also for mild
persistent asthma.
Asthma patients with milder asthma are typically
treated in general practice. Among those treated
with short-acting bronchodilators only, there might
be a group of patients with under-treated asthma
because of unrecognised severity or changes in the
severity of the disease. The patients may be
unaware of other treatment options or just accept
the symptoms and therefore do not report the
frequency or worsening of symptoms. Identification
of patients not well-controlled is the first challenge
to achieve better asthma control for this group of
patients. The next is to choose the most effective
treatment for the patient.
Results from this study showed that both study
treatments markedly improved the asthma control
and lung function, but patients benefit from
significant greater improvements in asthma control
and lung function by initiation of maintenance
therapy with the combination treatment S/FP
compared with the ICS FP alone.
Analysis of the primary efficacy parameter
showed that patients receiving S/FP as initial
maintenance treatment achieved a significantly
higher percentage of symptom-free ‘dayþ night’s
than those receiving FP alone.
The sub-analysis of symptom-free ‘dayþ night’s
of patients classified with mild asthma also showed
a statistically significant difference in favour of S/
FP compared with FP alone.
The analysis of secondary end-points for symp-
toms and use of rescue medication for relief of
symptoms, also showing a statistically significant
treatment difference, supported the conclusion of
a treatment difference in favour of S/FP vs. FP
monotherapy.
Findings from other studies conducted in
patients with asthma symptomatic when previously
treated with short-acting bronchodilators alone
have been published. A 4-week pilot study
compared Sþ FP with FP alone,8 two 12-week
studies compared S/FP with FP,11,12 a 4-week
study of S/FP without comparator,13 and two
studies with formoterol and budesonide that
included ICS-na.ıve as well as ICS-treated pa-
tients.14,15 Symptoms were not the primary end-
point in any of these studies.
The 12-week studies comparing S/FP with FP
alone differed from this study by allowing treat-
ment with LABA up to 72 h before enrolment.
This study confirmed the preliminary finding by
Pearlman et al.8 Patients symptomatic on as-
needed bronchodilators alone derived greater
benefits from initiation of maintenance therapy
with salmeterol and low dose ICS than ICS alone.
The treatment difference was significant for the
asthma symptom scores and percentage of days
with no asthma symptoms.
A 12-week study comparing S/FP with FP alone
also showed that S/FP treatment was significantly
more effective than FP alone in improving the
percentage of symptom-free days and days without
use of rescue medication for patients with asthma
not treated with ICS pre-study.11
The S/FP 50/250 mg study without comparator13
showed a baseline percentage of symptom-free
days of 20% in patients with mild-moderate asthma
which is similar to the percentage observed in this
study. The percentage of symptom-free days
increased to 70% after 4-weeks treatment with S/
FP. This is also very similar to the percentage of 66%
seen in this study.
The significantly higher improvements in morning
and evening PEF observed for patients who were
treated with S/FP compared to FP alone are in line
with findings from the pilot study with Sþ FP8 as
well as the two 12-week studies with S/FP analysing
lung function as the primary efficacy para-
meter.11,12
Two studies with formoterol and budesonide that
included ICS-na.ıve as well as ICS-treated pa-
tients14,15 have been published.
The primary endpoints in a 7-month study
comparing budesonideþ formoterol with budeso-
nide alone were the time to achieve asthma control
and time to first asthma exacerbation.14 Patients
were allowed to use short-acting b2-agonist
alone or with an ICS pre-study. 2/3 of the patients
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were treated with ICS pre-study, 1/3 were not.
The treatment difference in favour of com-
bination treatment vs. ICS alone was signifi-
cant for the primary endpoints as well as for
symptoms, rescue medication use, and lung func-
tion. It is concluded that combination treatment
enabled asthma control to be achieved more
quickly and in a greater proportion of patients,
regardless of whether or not patients received ICS
pre-study.
O’Byrne et al.15 reported the results of a study in
patients with mild asthma who pre-study experi-
enced symptoms while either taking no ICS or low-
dose ICS. The study was of longer duration and
included a larger number of patients. The aim of
the study was to determine whether regular
treatment with low doses of budesonide, with or
without low doses of formoterol, would reduce
severe asthma exacerbations and improve asthma
control (composite measure) compared with pla-
cebo. The patients were treated for 1 year.
Symptoms, rescue medication use, and lung func-
tion were studied as secondary endpoints. In
consistency with our study maintenance treatment
with a low dose of ICS reduced the percentage of
poorly controlled asthma days by more than half. A
statistically significant difference in favour of
combination treatment was shown for lung func-
tion. Improvement of all other outcome variables
only achieved statistical significance for patients
previously treated with ICS.
This is not consistent with our findings showing
that the sub-group of patients with mild persistent
asthma had significantly better asthma control with
combination therapy compared with ICS mono-
therapy. It is not possible to say if the differences
in findings can be explained by differences in
patient populations or drugs.
The importance of identification of under-trea-
ted patients with persistent asthma has been
emphasised. Daily asthma control can be improved
significantly by initiation of maintenance treat-
ment.
The findings in this and other studies conducted
with similar patients suggest that regular main-
tenance treatment of both inflammation and
smooth muscle dysfunction may be necessary for
the optimal management of asthma from an early
stage in treatment.
The significant treatment difference in favour of
combination treatment in the group of patients
with mild persistent asthma is of importance
because it suggests the consideration of an update
to current asthma treatment guidelines to recom-
mend initiation of maintenance combination treat-
ment for mild persistent asthma.
In conclusion, S/FP 50/100 mg bd is significantly
more effective than FP 100 mg bd alone when used
as initial maintenance therapy in symptomatic
asthma patients currently treated with short-acting
bronchodilators alone, also for mild persistent
asthma. The patients benefit from significant
greater improvements in daily asthma control and
lung function by initiation of maintenance therapy
with the combination treatment S/FP compared
with inhaled steroid (FP) alone.
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